Home

Produzione Me lunghezza pi rads 3 prostate biopsy opportunità sconto Irrigazione

The Radiology Assistant : Prostate Cancer - PI-RADS v2
The Radiology Assistant : Prostate Cancer - PI-RADS v2

Followup of Men with PI-RADS™ 4 or 5 Abnormality on Prostate Magnetic  Resonance Imaging and Nonmalignant Pathological Findings on Initial  Targeted Prostate Biopsy | Journal of Urology
Followup of Men with PI-RADS™ 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy | Journal of Urology

Gallium 68 PSMA-11 PET/CT Imaging in Patients with PI-RADS 3 | Journal of  Nuclear Medicine
Gallium 68 PSMA-11 PET/CT Imaging in Patients with PI-RADS 3 | Journal of Nuclear Medicine

Prostate Imaging-Reporting and Data System (PI-RADS) | Radiology Reference  Article | Radiopaedia.org
Prostate Imaging-Reporting and Data System (PI-RADS) | Radiology Reference Article | Radiopaedia.org

Diagnostics | Free Full-Text | Does Adding Standard Systematic Biopsy to  Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of  Clinically Significant Prostate Cancer? Should All Patients with
Diagnostics | Free Full-Text | Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with

PI-RADS 3 Lesions: Does the Association of the Lesion Volume with the  Prostate-Specific Antigen Density Matter in the Diagnosis of Clinically  Significant Prostate Cancer? - Beyond the Abstract
PI-RADS 3 Lesions: Does the Association of the Lesion Volume with the Prostate-Specific Antigen Density Matter in the Diagnosis of Clinically Significant Prostate Cancer? - Beyond the Abstract

PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and  MRI-directed Biopsy Pathway | Radiology
PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway | Radiology

Analysis of PI-RADS 4 cases_ Management recommendations for negatively  biopsied patients
Analysis of PI-RADS 4 cases_ Management recommendations for negatively biopsied patients

What is PI-RADS and why should you care? | THE "NEW" PROSTATE CANCER  INFOLINK
What is PI-RADS and why should you care? | THE "NEW" PROSTATE CANCER INFOLINK

JCM | Free Full-Text | New Biopsy Techniques and Imaging Features of  Transrectal Ultrasound for Targeting PI-RADS 4 and 5 Lesions
JCM | Free Full-Text | New Biopsy Techniques and Imaging Features of Transrectal Ultrasound for Targeting PI-RADS 4 and 5 Lesions

Evaluation of a multiparametric MRI radiomic-based approach for  stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic  lesions | Scientific Reports
Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions | Scientific Reports

Prostate Imaging-Reporting and Data System (PI-RADS) | Radiology Reference  Article | Radiopaedia.org
Prostate Imaging-Reporting and Data System (PI-RADS) | Radiology Reference Article | Radiopaedia.org

The basics of PI-RADS scoring and how AI can help
The basics of PI-RADS scoring and how AI can help

The Radiology Assistant : Prostate Cancer - PI-RADS v2
The Radiology Assistant : Prostate Cancer - PI-RADS v2

EPOS™
EPOS™

JPM | Free Full-Text | Equivocal PI-RADS Three Lesions on Prostate Magnetic  Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted  Biopsies
JPM | Free Full-Text | Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies

Early experience in avoiding biopsies for biopsy-naïve men with clinical  suspicion of prostate cancer but non-suspicious biparametric magnetic  resonance imaging results and prostate-specific antigen density < 0.15  ng/mL2: A 2-year follow-up study -
Early experience in avoiding biopsies for biopsy-naïve men with clinical suspicion of prostate cancer but non-suspicious biparametric magnetic resonance imaging results and prostate-specific antigen density < 0.15 ng/mL2: A 2-year follow-up study -

The basics of PI-RADS scoring and how AI can help
The basics of PI-RADS scoring and how AI can help

Life | Free Full-Text | Considering Predictive Factors in the Diagnosis of  Clinically Significant Prostate Cancer in Patients with PI-RADS 3 Lesions
Life | Free Full-Text | Considering Predictive Factors in the Diagnosis of Clinically Significant Prostate Cancer in Patients with PI-RADS 3 Lesions

Frontiers | Utility of Clinical–Radiomic Model to Identify Clinically  Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3  Lesions
Frontiers | Utility of Clinical–Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions

Prostate cancer in PI-RADS scores 1 and 2 version 2.1: a comparison to  previous PI-RADS versions | SpringerLink
Prostate cancer in PI-RADS scores 1 and 2 version 2.1: a comparison to previous PI-RADS versions | SpringerLink

An integrated nomogram combining deep learning, Prostate Imaging–Reporting  and Data System (PI-RADS) scoring, and clinical variables for  identification of clinically significant prostate cancer on biparametric  MRI: a retrospective multicentre study - The
An integrated nomogram combining deep learning, Prostate Imaging–Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study - The

Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA  Density Strategy for Clinically Significant Prostate Cancer | Radiology
Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer | Radiology

PI-RADS 3 lesions: Does the association of the lesion volume with the  prostate-specific antigen density matter in the diagnosis of clinically  significant prostate cancer? - ScienceDirect
PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer? - ScienceDirect